Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 9

ACCELERATING THE DEVELOPMENT OF CURATIVE MEDICINES WITH FUNCTIONAL IMMUNE PROFILING
DSA can increase T cell responses and contribute to
mixed allograft rejection.
In the study by Xie, et al., researchers sought to
characterize the individual T cell activations resulting
from these processes using a human immune system
mouse model of allograft vasculopathy. While the
researchers had previously analyzed bulk CD4+
and CD8+ TEM populations and found increased T
cell proliferation and overall cytokine production,
they noted that the functional heterogeneity
of immune cells prevented them from drawing
conclusions about the effect on individual T cells
within the population.2
In order to do so, the study
used IsoPlexis' single-cell proteomics to resolve this
functional heterogeneity and uncover the individual
immune cell subpopulations driving mixed rejection.
IsoPlexis' Single-Cell Proteomics
Reveals Drivers of Frequency and
Polyfunctionality Among Both CD4+
and CD8+ Proliferative TEM
Cells
Associated with Transplant Rejection
The study found that treating IFN-γ-primed human
ECs with PRA significantly increased the stimulatory
effects of ECs on isolated peripheral blood allogeneic
CD4+ and CD8+ TEM
proliferation. When ECs were
pre-treated with an IL-1 receptor inhibitor, (IL-1Ra)
the effect of PRA was markedly diminished. The
use of anti-IL-15 blocking antibody significantly
GENengnews.com | 9
Nanoclustering / Science Photo Library / Getty Images
http://www.GENengnews.com

Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines

Table of Contents for the Digital Edition of Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines

Contents
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 1
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 2
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - Contents
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 4
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 5
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 6
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 7
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 8
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 9
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 10
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 11
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 12
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 13
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 14
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 15
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 16
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 17
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 18
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 19
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 20
https://www.nxtbookmedia.com